Psychiatry

Abusing psychoactive substances, such as ADHD medication, cannabis, and nicotine, not only creates an addiction but can impact mental distress.

A phase 2a open-label study found BL-003 for treatment-resistant depression was well-tolerated and any acute effects resolved on average in less than 2 hours.

A new study found sleep and emotional well-being are impacted days before women get their period.

In a new study, investigators evaluated if social contact influenced the age gap between biological age, estimated with artificial intelligence (AI), and chronological age.

In a recent UK study, more than half of stroke survivors developed depression within 18 years.

The hospitalization risk was reduced to up to 75% for patients with heart disease treated with both antidepressants and psychotherapy to manage anxiety or depression symptoms.

Bionomics announced the release of the full dataset analysis of the ATTUNE phase 2b trial; the data suggests BNC210 for PTSD could have an advantage over approved medications.

Vice Chair of the Performance Measurement Committee Rebecca A. Andrews spoke to HCPLive about the challenges with performance measures for treating major depressive disorder.

In an interview with HCPLive, Rebecca Andrews, MD, provided insight into the way the American College of Physicians voted on the performance measures for MDD.

A new study found late baby boomers and Generation X reported greater levels of loneliness than early baby boomers and the Silent Generation.

Lindsey Venesky, PhD, discussed how a mental fitness vocal biomarker tool could identify mental health symptoms people might not even be aware of through their voice.

“Having a previous anxiety disorder before a crisis occurs can be a blessing” — a new study found therapy for anxiety before the COVID-19 pandemic helped individuals not have increased anxiety during and after the pandemic.

In an interview with HCPLive, Daniel Karlin, MD, discussed how their phase 2B trial demonstrated MM120’s durability through week 12 for the treatment of generalized anxiety disorder.

Now, 4 years since the start of the pandemic, how has sleep been impacted? Sleep experts provide their perspective.

A new study found women (1.64) had a greater hazard ratio of depression for CVD than men (1.39).

Acadia Pharmaceuticals decided to stop conducting further clinical trials with pimavanserin for negative symptoms of negative due to topline results.

In an interview with HCPLive, Viktoriya Karakcheyeva, MD, discussed how women healthcare workers experience more burnout than their male colleagues.

A study found a 1-percentage point increase in the population with medical debt was associated with 18.3 more physically unhealthy days and 17.9 more mentally unhealthy days per 1000 people for 30 days.

This psychiatry month in review spotlights new research on detecting and treating major depressive disorder with AI, FDA’s Complete Response Letter for roluperidone, and more.

A new study found menopausal hormone therapy was associated with a significant reduction in depressive symptoms over time with a greater reduction combined with antidepressants.

People experiencing homelessness exhibit similar rates of morbidity compared with housed patients, but a longer adjusted length of hospital stay.

Cancer patients with behavioral health disorders, such as substance abuse, eating disorders, and sleep disorders have a 7.76% increase in health care costs, a new study found.

Minerva Neurosciences announced the receipt of a Complete Response Letter for roluperidone in treatment of negative symptoms in patients with schizophrenia on February 27, 2024 despite clinical trial data indicating improved Negative Symptom Factor Scores and Personal and Social Performance scale scores.

A new study found female teens and young adults were more likely to have an increased antidepressant dispensing rate during the pandemic than male peers.

Check your knowledge on the American Psychiatric Association 2023 practice guideline for the treatment of patients with eating disorders.